HUE028595T2 - Nitrogéntartalmú aromás heterociklil vegyület - Google Patents
Nitrogéntartalmú aromás heterociklil vegyület Download PDFInfo
- Publication number
- HUE028595T2 HUE028595T2 HUE09794416A HUE09794416A HUE028595T2 HU E028595 T2 HUE028595 T2 HU E028595T2 HU E09794416 A HUE09794416 A HU E09794416A HU E09794416 A HUE09794416 A HU E09794416A HU E028595 T2 HUE028595 T2 HU E028595T2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- compound
- mmol
- added
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (7)
- t ¥«#iíleí, msaáy&t feövetfee# Äalfeöos M0& {1} w jp|gf$*«#sä$fef' slthgadhsté ¥àsérni á feá!##*: X-«fe p&toHI csapósl, is X s«4& 8#A; vs# A Ä&tvs:)C-«i 0^Ê ssöpoft, k* mmà.mptxt* ksâmxMëâ m^n, tmmM&wmn,. Μή&$βί0 mïpœî i Äly fel m ^kmm m&wmmmq&im is m»pík # «S|gsÄd feli <is<spöíí, s^bsststÄ fsat Ssegört, «hol U mim ®m&sM fel *m yémm cmpanbóí «, * «így á-ta# mm- hrnmem ¢5SÓJSöíi SbMIÉ £* VS|y Ő-íagÖ *f»más bfB#eÍfeSÍ SS(pi Ä ft SHMÍNÍ«(«ty i "4 srnpm í%gsife;Ml fel mi \iámm issàSÂeiïS öSöpöstfeÓl «* fsai liüyCfe áfesl) esoporfe &ub$sâM$ M <€r (¾ a&B} ssöptsri, edíól szstoitaeasies.) »* mm ^gptí&A M vm ÄW ssötófeam c#pöílbél S·· vsp :<Nagw ajOű& ls«^Síkfe|S4*C* slki!) ssöpöít:, mgy mh&äk&t 5* m# S4agâ smsíás S«ïÂfeit]{Cî»es slkilj «sepsfst, aöM #*ί*Μΐ&ΜΜ^ M és^a»t. %^ISótó: Β » «»: ssäteifesfefe* çsûpafthôl * m a U, va# 3, η Ον«# *, faMve, feo#Mtn 3, s % &4> ^.¾¾ Rr itaii^e^äs. iS^fetóí C^CS slkS cí»p?t Mo0m^& íMíesí^oít litor^spsrt, C^alfeöxicsöpä^^gy i^ogéa csoport, B Ähi csoport, sæoMMiimftfeii ssspc^ stó » ssÄigtssßaCsfe) 1-4 «soptffe mmly ÄgpfaSl M «p.'^tety« »!Ä®«pM ^ vegs HHagö aromás fcë^lfeig <®ψ®,: saateM ¥~ y&gy i(¥fc# ówöbs«» 5«»Ä1 Ä? * ·8?»1&$χί1κ»8^' W cs#otl s??*äiy i%g«ifcsSI fei ym ssfepspivs mpöáé# '& va# mposm feOvoteO feéplsi (SI) rpprsscífe&gaafeol δ-’ és |f plÄgy&s %gSSÄ? feiî csÈp^.:si^^t fc»U ftsogfttfe ahoi A 14«νι^*μ$ t®g«^ JtihP *δ®8&»: csoportból % 5-vagf »* csapit, vagy ssäibssÄ s- vs# 6-ugó wwoâs tettmxMil empan, *£#« sïsMsuej^s^ 1-4 *m? mggsâssüM ms mmmmmmm^ U ssM^i®fess«s «sö|5<st ö .mqtâfy #»# # fegvsifeeÂfeôi; C^Qs alkil SSógáíg MçlrpxiliA-C« aildl) ssaporfe m<mMCr%* Ä1) csapa^ διΟβ|^(€^ agd!) mpm, '^C% cifelasifeli^ €Α O&Iös&ücselest, ßr€*ternitepsit. CrQ. siklód ««open, ötekl csopte €V€$ altat «Söpört, hsk(§é((CrQ «fal) csoport, CyC* «Ikötkt csoport, CrC« stótolM osöjs0¾ Cj-C» «aktelfoal «opte teáp csoport. í'í*Cs tekrte csoport, ^(€(-1¾ älkiljarsisss <ssöp% testete ssépp, #v-€«, tei}kteoatete -mipeá, (SVC* MW (Çj^s «opta tel! «soport, iCrQ sllílite^sai! «sppprt, ksrtat csoport, feil« tek!)!có?tall csoport, kte»|i coopork (Cyc< ÄiMdNMA*i export, Ætï}m(mk$é<$nî} csoport, ataoszulfOm! «söpört, (CrQ -m&sá, a^SrC* mpm etette®*. te> esopo«, «s htepsosopte 2. te h igtei**» teíiii vegyül«! sorsak ^^ÄäsäÄg tepdkte te amelyet » kövte^SlÄss ΙίφΜρΐ) spprs^l
- 3. Ax U sgésrypoot ssaiot! yegyta vagy »mmk .tegvsctesxetlleg elfogta*^ sója, amolyet « MyteM Stetes M0i :|ΐ*2) ^ps^asÄtelít** kiá^ntem Cr%> slkl! csípős, tete»(Cr£* tel! tepte $ír€s ρϋ® osspört, ^k8) €r<% teoÄI tepte Srtetemil (Söpört, €~€* alkirill esöpört, €)-€$ ÄSsasItei! tejte* feróál mopori (^^»Am^sieéb^ csoport, tete*5®* »prfe |€Γ€*. äskHspsso^tessit csoport, 4$Ct*C& csoport, ssRipmjIlposI mgmfc. (€ä*€* Ältetetetet csoport, vsgy $(£<*£* teöte'ae^fößii «sofort, tetepk !?* ilggtteäM teC* ÄS cssööort, φΜ) -mmm. <€*€* Cj~Cs dkloste csoport. CrC<( steril esoporl, teC« slkte csoport, MMrom £**£« aterä tepöil Steil csoport, |CpÇ* aikSlktete esoptsst, da» csoporti, vagy tkksgáfi ßsopört, és k kivagy2. 4. Λ 3, Igésypom steaii vKgySiot, yagy sósak gvé^^s^tslőf altbpádsíö δφ» «bol Márogéo a&Ä «ste**> <*¥% oidps!kdH^5"Q^k^«Sö|?wt hs!ogte&s*£? te!) csoport, Ote teptel eseperk Cj-C* altat csoport, vagy Cj^alklsM csoport, Φ Cröxtm mm> häfegmßrts mm mm' $ ~5 csoport ,. ajod? ki vsa y#ssääR* « cssspönbdk totof M kövsitoiäliÄ fiús# esopött ás kto oppört, €ÄeliÄilcsöp^ cíétmmm nmmpomys^ klár «ζψΜ, μ \ k vggîf i. 5, A '& iglîîj^snf sgerkti vggysto vsgjjr sassk gÿé^'si^ssk^^ë clf«g&Ä*& s$& 8&# *** €(-¾ mm csoport, ás k 9. & Ä® Igéöypösxí: S^Hsíi vegyik* 3 vsgÿ ÄSk gk^gp^í^Kskteg slggsÂsié söjg, ahol R?s §g! csoport, « k ö. % M 1. $gs&«^pst sarkai «©Λ :W$$ afusak’^vigpas^ssikeg gifôiiÉ&tè séjs, sspclyet «she*-Φ iigk|CrC2 aikl) mpm vagy #11);: mm·. *M- ® sa&sgtrtusnaiek) 1-3 csoport, &««lv IlggáfeSi: tó* vákssxtvs ís ssifegö^^i·«1 csopcat, æfiôlg# k$\$!|«aÖliMfc :CrCs sÜ mm. ka&#«#r % àkk s Megárt mpMták) í«5 nsopm;m^ '& vü Plas^ya, a es^sö#éi smfy II követkessőtósókÍkpr-í9«föa*:)lg kiér csepeg ílsto ««open, és Iád? sagest '$*  % Ii&s#e8* sajtol valaki vagy mmk shöf •E* Μ*®!! esope** vagy sætesgMi értilmglö csoport, sSké s sM?agkIs®J^sk) 1-3 mpm &gipte$ » amel* ki vsa v&säfvs telrfk&ns osopr&to s2, & ssæâ^rtèise® m&m «2 »rnmmtym Mvm&ßm'. mM: csep»*, tífisospeiS csoport, ás, íkor csoport % As I igénypont smm. yégpSet ysgy *xtm& gyógysmlssstil«§ ëh§mm- s#k m*km g kavctksgê IM&JOS tóflsi (Î'I) fcpragsaill1% -te i - ig^^iHsksgsîlàïl yggÿiysï ;¥δ$^ ásnák gy^gypsvrisctoiiog dJog&cliskö sója, sanely«? s{crc* atonal ·*&# wä Mi«g«siCCj^ ÄilJ «sofort Cs«Ö4 sikkÄst «scprik Cr&t steil essest vsggjf Cj-C* sMßlS . j« Sv .«14k iVlvà ' CkOpOtt. U< à 1#, äglsypoßi iípfössl: vçgpsie*' 'W®#: SíáKÉ'· ^fessáháíá: ölssl &** Q*ß* &É? «Sispostv Ά A& I- i !, igénypontok bâm^pœ- smkâ- vegyffe vagy Ä $ytyytmémék& «MpMfr sójáéból ,R; tebsss ssöisíjst, B< .fe Nîl. |&îypte fcfeoslyiks szüM **!§&&& vagy aaskk Mpeé»üÍ(í elfepáte si, sfelámgéí^^ CrCjsim^ hætegênfCr CsÄïrnimh aisd s teg&i^rnmmM Ή «spwfc Μ mstvrnmm t^?s*^»i«aefy'P köveisaitMii flösf esoposi és mos^m IA> Az 141 sietek Mï»!ylk& mskú vsgyÄ i**gy a«i g^ps^tósseöfcg elfopáte sofss* sliöí &* It5, -R5, és f* j$«á«gyie íö*get!e»üi Msfrsgés *œ» vagy «bőttaKpát
- 15, Az hm. i^pmm |áfSí#5te stósís ^gplst vagy »mák gyó^mré:teleg eifegsálaté 0jâ, Sfeïl ïôîsd%ylks %iea«a8í Βώχφϋmem· vagy S«#é«^*ö)í&..é8 mkäm$ks hiîÙOgés ate, Μ» A® í 4$,. î^énysmîtik feáaaeSysks *a«s®8i vggylttat vagy p& tyègyss^s«eip®g «llopteö s6ja. ahoi B saisi «sos»** y«gy: sæüteiîàâii: oaÉfói «Síp^ afcæî s ?>f ssepon fSgg?Ö«sSl, msày kl vss vâlteva §x«ltetes ssoprs&ô! «3, #. ste&Ptea ip «3 s «apport, assdy &i feSv^sMMi::·£*Α φΜχ^φύ, bstagàpCr €·> ûM). s«ûp8fi* shol s haiogés aasspai^ :H WPQ& as8$5f &»*** visssæïya #«%# :k$yeteôk^ ksôr «sepert, htexicso|îe5t, CrC>. dkoxt ««po«. ite asopan, <ks korcsoport 1% te \-m igésyptek Istelÿto wîM vsgyStet «sf «Ä gy^as^sásíiteg d&gsÄO sops, ásíB «sopostoî a következő képki(ite) r«prsste|iaskaï B* &»li s^testÄ fèsJI «sob®& g sísí^SíSsíscss^ l# esepos* g^ggetlesül., amely M vsa válásivá «kôlassÉfeeos cat$®tè&i φ> S>tagá :8Ä&s htststodklll cstspojt, vsgy aai&Sïliïs SAágó esopa^ ÄI a J -3 mpm Wÿ^faM-, :$®φ kl vas väte» 'Sa^fcssaSfeM». csrpssiW Ä B-* feil «ssop% MM «bel & l*$ tmm ffiggMM* sîssly M m ää .trtwÄai esopÄt s4 pÄI ssepO. vs# :sæ&s»8sM pÄ «sop^ äisöl a febâxiMa^ak.i Kl asaprl afelÿ iis Va& Mitüt sfessaifeas MM» «sefs®»: -a4· & '«stí|ía^. asiseSy IÉ SsÖvMMlMIl 0: -¾ Ml «sp«t M^ft{C. -Cs MO ®^pä% f€r& eitósÉÉK^A #®> <$ΜΚ* CjCs Mö&M «feSört, CrC* älkssNs#^ Ssmil mpst, (¾¾ #C|fe#pli mpsst, desm'd^m, ihm siûpùti, kié? «sep«, és mim csàpâé, és $»MMssn$ .«Μ # a csföpíss, amely kl! kPafesÂ# OrC*. älkk ssspmi, M^&sCOrO* Ä) sssprO M&mà mp^% Ογ€4 a3ks*i s^k# iawsaa^p:, brfe csoport •'IS;. M MS. ipl# slfcgsdfeê $φ, si# P csoportot «K feofelfeS 0¾ sepeM1#1si# Bx* *btro#ferpss& 34*0 éM kfeioeltóp smpmi v»gy miï&Êôtèk »««^jénteitebntt.^âM Mk-lsaseSiiM. ahol a $2#sfe.fep{ek> 1 vegy 2 «sopon ibggetterâi M si va» vâlppvs .a^fe^stfess «opposé B  Ml mspm> Mp®, Ml $:ρώ*Μδβκ$(9^ I vsgy 2 esepït IliggeSimSl, feely 11: va» vfesætvs sm^Pfeas esogertóö?; pÄI csefet vagy möbsPiaält pMèli «sepri, âi&î s SÄüBsKÖöjeKsisk) 1 vsgv 2 csefpé«' &/&&&&, *mly M: vas vâlssPvs sPbsPtfe& csoporti# «7, sPkfetmcns msp&ti ®ô « fefet, wœ$$ iîi k8feks*^Ä CrC4 alkM esôpori,.. iglÿpsÎCî'-Oj alksi) csoport, æbel a àalsgÉ* çspôf?(ôk) («5 «sepert, amofy ÎÜ va» v&làsaîva s csôfPk!#. fesly &8 kfesfegbklÄ Bsor «söpört és klfecsoport, (€^4¾ skleaMHCrCj Ä«) csoport* Os A eMoa&ll (€jÆkÂOkar&«sfi «sc##, atom. csoport, Iteíípepö^,® klèî assp<M, és mihMhums esöpsrt Φ a csoport sofev síi kOveikerôM#: CrCj alkii e$oï>on> brtinm csoport Puprcsoppjfe Mór csoport, IS. Λ2 MS. igôsyi&sotok hfesoiÿika sæm# vogylfe. vagy aapsk &yögysofes-fekg eifopsksiSMl pis csoport Μ » válásaivá a kôvetfeçë crt#srtfeél vagy feport, amely P vm vite**« a teM aW a ssafeÄiass egy esp«P, sspsly |%gktlp§(ki vsai 0ímm mÈæt&m$ MippMÎ Msaufes«Ütiä«ns ssoprt φ &%mspQft emaly ál kiHpk«ESkB&k ^rC* Äk£pp*k kateg&?{£:~ Ck Ä1) cse&ott, almi s fe&ípgfe .csty«t^^ |*$ esöfiösi, amely kf sáa v$£agj$i$ ä eppóííbék ps&íy Aü ^yd&$2§tdï$! Biiöf eSíJföst &i kiér essport, etllopss^ü esepíkk Á^&tlksrWm! csöpög stgso «söpri, i»esí^?áés ä «sepert, 2¾. M W& spR^»k feteöeívfe mmâ Ϋ*$0® '^ψ *&& iPgpm^pB5ég élÉpás# &&!&> Μ Β ssopriot § S#eaík®pMgfei ÖSi); rpr&æÂts,^í«i B!s ésöpftli v« váltévá « kävstk«2$ αρρή&Μ vsgy easpest, a&seíy isi va» válaMys* pvsipp PsöpríMi fs sMssxííMk, &h&] *. s«^«ke«ms agy «soparîi mtèk? Bi^sBsns? kl vsa S£öbS2ti»i§ «ssprâséï s£As: s«pspttt«ï»ssttj>îst ix§ « ^pep sasaly AB feBveik«pkbëî;: mp# esoport, s*s cs«pöft, «s klór csoport. ti, M L igénypont sssmti vegyük* v&gy a»nak gyAgys««rAms:í% elfogadható sója, amely kl van ygasEíva a csopprlBAÎ, «Rely àll s ksvefetökMÍ: •^|2hí^4í4^te0^^^-4H^I|sss«WM«^^-ilJpro^no!i>emii^o^í'^||ifili,Pö!»á-'kaaEfes®íáíiNSí^ 4· (3-|;4-k^r'<4-Miáro^^©n^>ía:ö>i«^Í^-kt'Íp?í>psríOít>Síisíy4í>^ I ~e%|rrol-3 4wBokilSks<i #» |3-f^*^Íiv{4~biörfexsífe^i)sx<»í&aöí.'S't!lpri>vírííi<íj ;} mjfàfc· | ~ed Sj$m&sS4s&tt:b&dBsy; 4* 34(4··&Μ&1§κη1}4^^ aísiss>l ^jfplô*4*3 ^ksrboAay? 4<·:Ρ"Ρ^Ι*^{44\^^>ί^8Β)1^δ^Ι-3^0'2^^®80φ^^0ΐ|^Η0ΐ0-!ί^ίΙ^ΐΓόΙ4·<1<^βΧΚδδν; 4- (344ékíbf*3#*biÉms&k1^ l^lpinsl^ksffeôîïMsa^;3-Îl0O^m|^ô^^ÎïîO'i^ï%iè^t-34issfei>ïcûs3;v; és
- 22, Gyógyszerészi me&zte®, wmiy. l5&îés«ys| íamimaz *«. Igásyposíök bSto#Íe m0m ^mmm 33. Λ 22, ïgéB^fesî Sksrkbi \mm>^k Mmstôêâm bsps^pstak, appâte»»» «tôÂMs^ssmviiim,. snerbskferöíss. vagy II tlpasô àisb4?ss mellkas k««eîssèfce» vagy jksilaxiaâfe 24. A 2& îÿkypm Mmmüàm kssalPta vâ|ÿ pbSlmlsébss. 25v A '22. tpsypsi mê^i hsmpotkkà, ^0:-m&à>sÊmfat· mwtMm *mtm$m Mgfp-ôfllaxMhsït 23. A 22-.: igppest S®e#ks kanadaié, Mbäsaakksm h|5èîtî%&«ÂSife vsg£ iktbkMisfes steatohspainis kfczaiàsèbsa. y®·· pTiâlîsxssâbaa, '2?, Âz 1*21 %á»yp«iÉlt ysgy jssmk pbpsgpksspkg slfögÄabä sôf» SkasâââiSïs blpsfjjpSsssk, áfeHpkkbks, lfÉi^afeoüa^«s spi!k&.;æ$i^kâpâ^. vagy M pásé M .M %*á% igáppbbsk bámsíy&e smtMi vsgyikä wi$& sója feLbssxwÄra sfsbpîés ïæm^feessî vagy 8f5>Slasts#sH. .#, Ακ ί«2ί. %éap<p«ök MEskjyj&e fesifM VbgyÄk vagy «safe gyôgpægÂstifeg eJfepábssb 3{j. As i--21, igpypbtbk b&rsisslysk« ssapbti vagybkv vsgy sœak gydgpÄässstifeg gl&gsdkab? séjs. »assptes Mps^ßssä^M< vagy baÄ&PÄs *i»é^Â' k«2$l&#«« vsgy
- 31. As 12 L %&3ypo»tök bkmsslyike sasdott v$gpÄ mg$; asjaik äpbg>^e^®®däeg elfögadhs® sója r«lh8»s}5steag><0gyssofk«at
- 32. As 1-21. Igéayponiçk feéftîslyiks sxsrkb vegyUJ«* vagy amnak gyégysgæréssgîileg vlfogaáhaíö sà}& MmmsÊkk-Mÿ&mr «IMiiMsPan ftlhassnálásra blperflpkktsma. Äspidmia, îpb ^®t8^s»:is Asvmau sAsnvsklvrvxk vagy Ίϊ íjpsS bisbvte mvlHms ksssMsbbva vagy pmfíía&tsábsm. 33. M 1-2 k igésypöaíok bármelyike ssedaíí vsgylikk vagy srnsk gyógysseíVsmüsig ç]%yvibaîà sáp foShasanklása gybgÿsser sióálibáxáb&nfatbasgaáiásra dislipistea k«*ates*b«» vagy profilaxisában.
- 34. At 14í. %4ftjp«kok bäravbvlka szsÉaÜ «egytübf vagy ássák p%yssékésb8dl«|; elíbpáptb sója MkassnédAV gybgys&v· gidállMsáb«.« %>í<i ssaíshöbssnjs akvaítóí 33. A*: í*21 ípRyfbbíok bánjpyíí® sxarM vsgy$<$ vagy «Ä gy^s^pspbieg dfejpíteé sbjjg PbssæaÂss lyègyyrsf ÄSMsärs Mprtsígtlm'yéöík vagy nemslkobylos si&atöppatb& kspéafe vagy pjysfcNbas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008178377 | 2008-07-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE028595T2 true HUE028595T2 (hu) | 2016-12-28 |
Family
ID=41507085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09794416A HUE028595T2 (hu) | 2008-07-08 | 2009-07-07 | Nitrogéntartalmú aromás heterociklil vegyület |
Country Status (25)
Country | Link |
---|---|
US (2) | US8648103B2 (hu) |
EP (1) | EP2308838B1 (hu) |
JP (1) | JP5461398B2 (hu) |
KR (1) | KR20110025742A (hu) |
CN (1) | CN102149680B (hu) |
AU (1) | AU2009269178B2 (hu) |
BR (1) | BRPI0915473A2 (hu) |
CA (1) | CA2730078A1 (hu) |
CO (1) | CO6341610A2 (hu) |
CY (1) | CY1117503T1 (hu) |
DK (1) | DK2308838T3 (hu) |
ES (1) | ES2566529T3 (hu) |
HK (1) | HK1155443A1 (hu) |
HR (1) | HRP20160236T1 (hu) |
HU (1) | HUE028595T2 (hu) |
IL (1) | IL210498A0 (hu) |
MX (1) | MX2011000044A (hu) |
NZ (1) | NZ590790A (hu) |
PL (1) | PL2308838T3 (hu) |
RU (1) | RU2481330C2 (hu) |
SI (1) | SI2308838T1 (hu) |
SM (1) | SMT201600119B (hu) |
TW (1) | TWI435875B (hu) |
WO (1) | WO2010004972A1 (hu) |
ZA (1) | ZA201100183B (hu) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI435875B (zh) * | 2008-07-08 | 2014-05-01 | Daiichi Sankyo Co Ltd | 含氮芳香族雜環化合物 |
PE20141637A1 (es) | 2011-04-28 | 2014-11-20 | Japan Tobacco Inc | Compuesto de amida y aplicacion farmaceutica para el mismo |
WO2014065413A1 (ja) * | 2012-10-26 | 2014-05-01 | 日本たばこ産業株式会社 | トリアゾール・イソオキサゾール化合物およびその医薬用途 |
EP2920179A4 (en) * | 2012-11-12 | 2016-03-30 | Victoria Link Ltd | SALT FORMS AND POLYMORPHIC FORMS OF (3R, 4S) -1 - ((4-AMINO-5H-PYRROLO [3,2-D] PYRIMIDIN-7-YL) METHYL) -4- (METHYLTHIOMETHYL) PYRROLIDIN-3-OL (MTDIA) |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
LT3464271T (lt) | 2016-05-31 | 2020-09-10 | Kalvista Pharmaceuticals Limited | Pirazolo dariniai kaip plazmos kalikreino inhibitoriai |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
IL274557B2 (en) | 2017-11-29 | 2024-09-01 | Kalvista Pharmaceuticals Ltd | Dosage forms containing a plasma kallikrein inhibitor |
EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2006427A3 (cs) * | 2003-12-29 | 2006-11-15 | Sepracor Inc. | Pyrrolové a pyrazolové inhibitory DAAO |
CN101056635A (zh) * | 2004-11-04 | 2007-10-17 | 默克公司 | 烟酸受体激动剂、含有该化合物的组合物及治疗方法 |
AU2005305086A1 (en) | 2004-11-05 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists |
EP1824812A4 (en) * | 2004-11-23 | 2009-10-28 | Merck & Co Inc | AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES |
GB0503053D0 (en) | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
GB0505735D0 (en) | 2005-03-21 | 2005-04-27 | Glaxo Group Ltd | Compounds |
PE20070097A1 (es) | 2005-06-28 | 2007-03-08 | Merck Sharp & Dohme | Agonistas del receptor de niacina y composiciones que contienen tales compuestos |
WO2007015744A1 (en) * | 2005-07-21 | 2007-02-08 | Incyte Corporation | Disubstituted thienyl compounds and their use as pharmaceuticals |
CA2630012A1 (en) * | 2005-11-18 | 2007-05-24 | Dabur Pharma Limited | Targeted fusion proteins for cancer therapy |
EP1792901A1 (en) * | 2005-11-22 | 2007-06-06 | Bayer CropScience S.A. | N-(1-alkyl-2-phenylethyl)-carboxamide derivatives and use thereof as fungicides |
WO2007075749A2 (en) * | 2005-12-20 | 2007-07-05 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
US20090062269A1 (en) | 2006-02-07 | 2009-03-05 | Subharekha Raghavan | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment |
JP2009533436A (ja) * | 2006-04-11 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | ナイアシン受容体アゴニスト、かかる化合物を含有する組成物、及び治療法 |
TWI435875B (zh) * | 2008-07-08 | 2014-05-01 | Daiichi Sankyo Co Ltd | 含氮芳香族雜環化合物 |
-
2009
- 2009-07-07 TW TW098122847A patent/TWI435875B/zh not_active IP Right Cessation
- 2009-07-07 NZ NZ590790A patent/NZ590790A/xx not_active IP Right Cessation
- 2009-07-07 PL PL09794416T patent/PL2308838T3/pl unknown
- 2009-07-07 SI SI200931400A patent/SI2308838T1/sl unknown
- 2009-07-07 CN CN200980134944.5A patent/CN102149680B/zh not_active Expired - Fee Related
- 2009-07-07 WO PCT/JP2009/062331 patent/WO2010004972A1/ja active Application Filing
- 2009-07-07 ES ES09794416.9T patent/ES2566529T3/es active Active
- 2009-07-07 HU HUE09794416A patent/HUE028595T2/hu unknown
- 2009-07-07 KR KR1020107025572A patent/KR20110025742A/ko not_active Application Discontinuation
- 2009-07-07 RU RU2011104223/04A patent/RU2481330C2/ru not_active IP Right Cessation
- 2009-07-07 EP EP09794416.9A patent/EP2308838B1/en active Active
- 2009-07-07 AU AU2009269178A patent/AU2009269178B2/en not_active Ceased
- 2009-07-07 MX MX2011000044A patent/MX2011000044A/es not_active Application Discontinuation
- 2009-07-07 CA CA2730078A patent/CA2730078A1/en not_active Abandoned
- 2009-07-07 BR BRPI0915473A patent/BRPI0915473A2/pt not_active IP Right Cessation
- 2009-07-07 DK DK09794416.9T patent/DK2308838T3/da active
- 2009-07-07 US US13/001,806 patent/US8648103B2/en not_active Expired - Fee Related
- 2009-07-07 JP JP2010519777A patent/JP5461398B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-06 ZA ZA2011/00183A patent/ZA201100183B/en unknown
- 2011-01-06 IL IL210498A patent/IL210498A0/en unknown
- 2011-01-13 CO CO11003214A patent/CO6341610A2/es active IP Right Grant
- 2011-09-12 HK HK11109621.5A patent/HK1155443A1/zh not_active IP Right Cessation
-
2014
- 2014-02-10 US US14/177,000 patent/US9150563B2/en not_active Expired - Fee Related
-
2016
- 2016-03-07 HR HRP20160236TT patent/HRP20160236T1/hr unknown
- 2016-04-22 SM SM201600119T patent/SMT201600119B/it unknown
- 2016-05-13 CY CY20161100405T patent/CY1117503T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUE028595T2 (hu) | Nitrogéntartalmú aromás heterociklil vegyület | |
JP4324221B2 (ja) | Pparアゴニスト活性を有する誘導体 | |
WO2002006237A1 (fr) | Medicament comprenant un derive de dicyanopyridine | |
WO2004026841A1 (ja) | 新規6−置換ウラシル誘導体及びアレルギー性疾患の治療剤 | |
WO2012020749A1 (ja) | トリアジン誘導体およびそれを含有する鎮痛作用を有する医薬組成物 | |
JP2022521825A (ja) | アンドロゲン受容体モジュレーター及びタンパク質分解誘導キメラリガンドとして使用するための方法 | |
WO2006022374A1 (ja) | 2-フェニルピリジン誘導体 | |
RU2125565C1 (ru) | Производные фенокси- или феноксиалкилпиперидина и антивирусная композиция на их основе | |
WO2016031987A1 (ja) | オートタキシン阻害活性を有するピリミジノン誘導体 | |
WO2006022375A1 (ja) | 2-フェニルチオフェン誘導体 | |
TW202003472A (zh) | 鈣蛋白酶(calpain)調節劑及其醫療用途 | |
CN103080086B (zh) | 抑制前列腺素d合成酶的哌啶化合物 | |
JP2011157349A (ja) | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 | |
US20170107234A1 (en) | Tricyclic heterocycle derivatives having hiv replication inhibitory effect | |
SG178043A1 (en) | Substituted benzamide derivatives as glucokinase (gk) activators | |
CN114206836A (zh) | 新型吡咯化合物 | |
WO2017033966A1 (ja) | オートタキシン阻害活性を有する5位カルボニルアミノアルキル置換縮合ピラゾール誘導体 | |
EP2980085A1 (en) | Pyrazole derivative | |
TW201036962A (en) | Novel 2, 5-disubstituted pyrrole derivative | |
TW202409010A (zh) | 人類呼吸道融合病毒及人類間質肺炎病毒之抑制劑 |